Navigation Links
The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
Date:1/31/2008

DVT), usually in the leg, and pulmonary embolism (PE).

VTE is a common complication among patients hospitalized for major surgery or with a severe medical illness.

About ENDORSE

To date, ENDORSE is the largest international study performed in hospitals selected at random around the world to evaluate VTE risk and prophylaxis practice globally. Patients were enrolled at 358 randomly selected hospitals in 32 countries in Europe, North America, South America, Middle East, Asia, Australia, and North Africa.

The primary objectives of ENDORSE were to identify patients at risk for VTE among patients hospitalized in representative hospitals throughout the world and determine the proportion of at-risk hospitalized patients who receive effective VTE prophylaxis by using the definition of patients at risk of VTE and prophylaxis recommendations provided by the American College of Chest Physicians (ACCP) evidence-based consensus guidelines(2). The secondary objectives of ENDORSE were to define the global rate of medical and surgical patients at risk for VTE, define the overall rate of patients receiving appropriate prophylaxis in medical vs surgical populations and carry out analysis by country and region.

The study included two categories of hospitalized patients: patients in medical wards 40 years of age or older, and patients in surgical wards, 18 years or older. All hospital wards with acute medical or surgical patients were eligible for the survey.

About COR (Center for Outcomes Research)

The Center for Outcomes Research (COR) serves as the scientific coordinating center for a growing number of national and international outcomes registries. COR's responsibilities include maintaining patient and physician confidentiality, design of data collection instruments, data management and publication development.

Established in 1994, COR is an outgrowth of the Worcester Deep Vein Thrombosis Study, a five-year NIH-supported progr
'/>"/>

SOURCE University of Massachusetts Medical School
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Lancet Publishes Vasogens ACCLAIM Results
2. Vasogens Research Published in European Journal of Neuroscience
3. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
4. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
5. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
6. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
7. Researchers outline structure of largest nonvirus particle ever crystallized
8. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
9. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... received the second $1.0M tranche under a previously ... grant valued at up to $3.0 million to ... surfactant as a potential medical countermeasure to mitigate ... was awarded an initial $1.0 million under this ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
(Date:7/29/2015)... , July 29, 2015 US-Australian drug ... ) today confirmed it is committed to progressing its ... soon as practicable and to ensure the Company delivers ... Executive Officer, Iain Ross , said the Company ... the lead pre-clinical programs, discovery programs and academic partnerships ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company ... to regress atherosclerotic plaque, announced the recent presentation ... Division of Cardiology at the David Geffen School ... Heart Association (AHA) Scientific Sessions in Orlando, Florida.  ...
... 2011  If algae is to be the solution for America,s ... make that a reality. Applications are now available for continuing ... retrain workers as general science technicians in the rapidly expanding ... Approximately 55 students will begin classes in ...
... 22, 2011 Sequenom, Inc. (NASDAQ: SQNM ), ... announced the Company,s participation at the 23rd Annual Piper Jaffray ... November 29-30, 2011. Ronald M. Lindsay, Ph.D., ... Maier, CFO, will present on Tuesday, November 29, 2011 beginning ...
Cached Biology Technology:AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 3Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference 2
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... the winner of the Young Investigator Award by the journal ... regulation of neural stem cells. The $10,000 prize is ... judged to be of worldwide significance by a global jury. ... cell biology is the recognition that self-renewal and differentiation can ...
... not only eco-friendly but also has several superior qualities ... is moving towards completely bio-based products. The volume of ... equates to approximately five per cent of the world,s ... plastics are used in packaging, which puts special pressure ...
... with the quality of their sperm. The problems often ... with age. Sperm senescence can arise either before or ... a process known as meiosis. So-called "pre-meiotic" senescence results ... and results in older males having sperm of lower quality. ...
Cached Biology News:Plastic packaging industry is moving towards completely bio-based products 2Fitness for toad sperm: The secret is to mate frequently 2
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
fli-1...
Purified Mouse anti-Hu p120 Catenin (pT916) Storage Temperature: Refrigerate(2 to 8C)...
Request Info...
Biology Products: